FP14.11 Icotinib versus Chemotherapy as Adjuvant Treatment for Stage II–IIIA EGFR-Mutant NSCLC (EVIDENCE): A Randomized, Open-Label, Phase 3 Study

Authors :: C. Zhou
J. He
C. Su
W. Liang
S. Xu
L. Wu
X. Fu
X. Zhang
D. Ge
C. Chen
W. Mao
L. Xu
G. Shao
W. Li
B. Hu
J. Fu
Z. Wang
Z. Jianying
Y. Huang
H. Ma
Y. Liu
F. Ye
J. Hu
J. Zhao
X. Liu
Z. Liu
R. Xu
Z. Xiao
T. Gong
W. Lin
X. Li
L. Ding
L. Mao
Source :: Journal of Thoracic Oncology. 16:S232
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
Chemotherapy
business.industry
medicine.medical_treatment
Mutant
Phases of clinical research
Stage ii
Internal medicine
Icotinib
medicine
Open label
business
Adjuvant

Full Text Access

Tools